Menu Close

Time Is Running Out! This Friday Is Your Last Chance To Save £150 At The Pharma & Healthcare Comms & Reputation Advances Conference


Harness Digital Advances & Evocative Comms Approaches In The Post-Pandemic Landscape To Forge Deep Stakeholder Relationships & Drive Reputation & Communications Excellence For Pharma & Healthcare
Ensure Your Communications Add Real Value To Patients • Break Down Complex Issues For Clear, Transparent Communication Which Increases Trust • Digital & Social Media Communications Which Cuts Through • Outline Corporate Purpose & Evidence Action • Justify The Value Of Pharma During Economic Pressures.

A One-Day, Industry-Led Conference & Networking Event, 8th November 2022, Central London.  Send Your Team! Please call +44 (0)20 3479 2299 for group discounts! No Visa Needed From Most EU Countries - Find Out More.

28 Pharma & Healthcare Comms Leaders Delve Into Their Experiences, Knowledge & Insights In Driving Progressive Treatment, Health & Wider Organisational Agendas, Spotlighting Value, Advancing Sustainable Health Outcomes & Societal Wellbeing, Boosting Reputation, Deepening Stakeholder Ties & Championing Innovation & Patient Centricity.

  1. Protect Reputation, Reframe The Narrative: Create authentic comms approaches to capture the pandemic momentum and enhance company reputation
  2. Improve Public Trust & Combat Harmful Misinformation: From fake news to active mistrust of big pharma, comms methods to increase transparency and trust
  3. Communicating The Complexities Of Pricing & Market Access During Economic Downturn: How can we communicate value instead of price to minimise reputational damage and unlock ongoing stakeholder investment? New
  4. Interactive, Two-Way Patient Comms: Action patient feedback to improve ongoing communications and services Pioneering Approaches
  5. Advance Digital & Social Media Comms! From new channels to engaging content, cut through and achieve tangible reach with key stakeholders - Cutting Edge
  6. New Corporate Purpose & Impact: Outline and promote company ESG goals and benefits for healthcare initiatives to boost internal and external reputation - Fresh For 2022
  7. Winning Internal Communications: Increase internal advocacy and strong company cultures with purpose with savvy comms which cater to all colleagues – wherever they work!
  8. Government, Policy & Media Relations: Stay abreast of ongoing healthcare developments and carry forward the collaborative momentum from COVID to maintain relationships - Key Learnings
  9. How To Prove Impact? Measure campaign performance to assess impact and direct your comms strategies and priorities going forward

The Pharma & Healthcare Comms & Reputation Conference At A Glance...


Senior Brand

Advanced Topics

Satisfaction Rate
At Our Last Event

Annual, Market-Leading Event

Inspiring, Exciting

Why Attend Europe's Pharma & Healthcare Comms & Reputation Conference?

  • 3 Years Of Industry-Leading Insights & Networking Opportunities
  • Brand New Speaker Line-Up! Including Moderna, Merck, Teva & Many More
  • 4 Interactive Panel Discussions & Q&A: A) Reputational Challenges & Opportunities B) Digital Comms & Social Media C) Patient Engagement D) Government Relations & Policy
  • Dedicated Peer Sharing & Networking
  • 4 Facilitated Peer Discussion Breakouts: A) A New Treatments & Innovations B) Vaccines C) Crisis Response D) Diversity & Inclusion
  • 7 Perspectives From Around Europe

12 Years Of Market-Leading Events... Past Delegates Say It Best!

Now Is Your Chance To Get Involved In The Pharma & Healthcare Comms & Reputation Advances Conference | Call Us On +44 (0)20 3479 2299 - Get Involved Now & Save £1000!

Can You Help Comms Professionals In Pharma & Healthcare Achieve Impactful Communications? For More Information, Please Email or call the team on +44 (0)20 3479 2299.

Book An Exhibition Stand + 2 Delegate Places Now For Only £2,499 - SAVE £500! Exhibition space is limited and will be issued on a first-come, first-served basis.

Our 2022 Sponsors Include: 

28 Pharma, Healthcare & Regulatory Leaders Tackle Your Toughest Communication's & Reputation Challenges In 1 Day: Public Perception & Narratives • Reputation Management • Affordability & Reimbursement Post-Pandemic • Patient Engagement • Sustainable Health Agendas & Corporate Purpose • Digital & Social Media • Value & Stakeholder Cut-Through • Government Relations & Policy • Internal Communications

Harness Digital Advances & Evocative Comms Approaches In The Post-Pandemic Landscape To Forge Deep Stakeholder Relationships & Drive Reputation & Communications Excellence For Pharma & Healthcare: Comms That Add Real Value To Patients • Break Down Complex Issues For Clear, Transparent Communication Which Increases Trust • Digital & Social Media Communications Which Cuts Through • Outline Corporate Purpose & Evidence Action • Justify The Value Of Pharma During Economic Pressures.

A One-Day, Industry-Led Conference & Networking Event, 8th November 2022, Central London. Send Your Team! Call +44 (0)20 3479 2299 for group discounts! No Visa Needed From Most EU Countries - Find Out More.

08.30 Registration, Informal Networking & GIC Opening Remarks

09.10 Morning Co-Chairs’ Opening Remarks

Cheryl Pitcher, Head, Corporate Communications, AbbVie



Bernard Mallee, Director of Communications & Advocacy, IPHA


09.10 How Can Pharma Shake Off The Cloud Of Negativity & Misinformation To Increase Transparency & Trust With The Public & Be Perceived As A Credible Information Source?

  • COVID isn’t the only epidemic at our gates… how can pharma mitigate the impact of fake news online to create space for trusted, medically-sound information sharing?
  • Are there better approaches for pharma and healthcare authorities to work with media to combat the spread of misleading coverage or wilful disinformation and build trust?
  • Can we better harness the positivity of pharma’s role in the pandemic to further develop a strong, receptive public health environment for new treatments and innovation in other therapy areas?
  • From obesity to mental health to anti-microbial resistance, how can pharma achieve cut-through with the public while shining a light on preventative healthcare to improve wellbeing and patient outcomes?
  • Public trust is going to be paramount to future innovations and successfully leveraging healthcare data – so how can we lay the groundwork with our comms to increase transparency and secure buy in?

Speaker to be announced, please check the websites for updates.


09.30 Seize Comms Opportunities To Reframe The Narrative & Boost Company Reputation Across Key Pharma Stakeholders Within The Lens Of A Rapidly-Changing World

  • We’re in a changing world! To what extent do healthcare budget squeezes, swinging political affiliations, volatile supply chains, new governments and wider worldwide events shape the overall perception of the industry – and how can we positively influence that?
  • Safeguard against profiteering finger-pointing: enhance your voice and presence on key societal and welfare issues to continue to justify the investment in healthcare and be seen as critical partners to public health
  • All tarred with the same brush? Cultivate a strong company presence to break away from a single industry perception when there is a negative incident or crisis elsewhere in the sector
  • When many elements of the pharma industry are built on commercial sensitivity and intellectual property, how can we balance holding our cards close to our chest with an openness and transparency that consumers have come to expect from business?
  • Reputation stagnation: explore opportunities to reframe the sector and shift certain lingering prejudices from the last 20 years

James Read, Director - Animal Health Policy & Comms Lead UK, MSD


Justyna Joanna Konczalska, Head of Communications & External Engagement Germany, Sandoz



Adam Davison, Director of Global Policy & Communications, Babylon



Fiona Cohen, Head of Corporate Reputation for Europe, Teva Pharmaceuticals



Helen McDowell, Head of Government Affairs & Global Public Health, ViiV Healthcare


10.00 Perceptions Around Pricing: The Ongoing Battle To Communicate Complexity To Manage Multiple Stakeholder Backlash Around Pharmaceutical Product Pricing, Prove Value & Mitigate Reputational Damage

  • There are no quick, cheap wins in drug development! So how can we best clearly communicate the science and production complexities to justify price – and translate that to the public, patients, media, government, HCPs and payers?
  • When pharma is having to make difficult decisions to achieve affordability and market access – how can we clearly convey the negative impact this has on healthcare innovation?
  • Are there strategies that actually land well with the public and media to prevent the profiteering narrative from resurfacing and impeding traction with politicians and other key stakeholders?

10.20 Bonus Session; Reserved For Exclusive Conference Partner

10.50 Morning Refreshment Break With Informal Networking


11.20 Strategic, Engaging & Interactive Patient Communications Which Build Trust, Bolster Long-Term Relationships & Provide Holistic, Meaningful Support At Every Stage Of The Patient Journey

  • Go beyond one-off campaigns for sustained engagement with patient communities that increase trust, provide accurate information and truly add value to the patient-pharma interaction to encourage further contact
  • With healthcare systems under strain, waiting times up and critical treatments overshadowed by COVID, how can we communicate with patients to mitigate frustrations and minimise healthcare inequality in the face of ongoing challenges?
  • Seize every opportunity to close the loop and draw meaningful insights from patient journeys and communications to further improve patient resources and services
  • In the room where it happens… how can you leverage communications to ensure that patients have a seat at the table?

Clara Bentham, Head of Communications, Sanofi UK & Ireland


Marlène Elisabeth Spielmann, Associate Director, Patient Advocacy EMEA, Novocure



Stephen Head, Senior Director, Patient Partnerships, Astellas Pharma Europe


Paul Robinson, European Lead, Patient Innovation, MSD



Darcy Bowman, Director, Public Affairs, Gilead Sciences UK & Ireland


11.50 Delivering On A Clear Corporate Purpose To Deepen Impact For Stakeholders, Contribute To Business Resilience & Strengthen Sector

  • Health is wealth… how can we increase pharmaceutical industry-stakeholder collaboration to advance global access to healthcare and address future health challenges?
  • As health inequities enter the spotlight on global, regional and local levels, what should we do and how should we join the conversation to evidence pharma’s positive impact and tangible advances?
  • With governmental measures around social value and the UN Sustainable Development Goals, how do we engage in a constructive dialogue with investors and incorporate ESG into pharma performance narratives?

11.50 Perspective One
France Bourgouin, Director, Global Sustainability, LEO Pharma



12.05 Perspective Two
Véronique Toully, Vice President & Global Head of Sustainability, UCB


12.20 Discussion: Q&A with France & Véronique


12.30 Ethical Handling Of Health Data: How To Create Trust Through Establishing & Communicating Ethical Principles

Jean Enno Charton, Director Digital Ethics & Bioethics, Merck



12.50 Morning Co-Chairs’ Closing Remarks

13.00 Lunch For Delegates, Speakers & Partners

13.30 Informal Peer-To-Peer Discussions Peer-To-Peer

a) New Treatments & Innovations Peer
Hayley Wood, Head of Public & Media Relations, Corporate Communications, Bayer


b) Vaccines
Luke Mircea-Willats, Director, Media Relations & Communications, International, Moderna


c) Diversity & Inclusion
Jill Pearcy, Director, Reputation, ABPI


d) Crisis Response
Alicia Custis, Associate Director Of Communications, Pennine Care NHS Foundation Trust

Co-Chairs’ Remarks

14.00 Afternoon Co-Chairs’ Opening Remarks

Fiona Cohen, Head of Corporate Reputation for Europe, Teva Pharmaceuticals


Anna Schmelcher, Director Corporate Affairs (Europe, Latin America, Middle East, Africa & Canada), Amgen


14.10 How Is The Industry’s Social & Digital Campaigning Helping To Tackle The Large & Looming Issue Of Antibiotic Resistance?

The pharmaceutical industry is leading the movement to tackle anti-microbial resistance with growing recognition of this great global health challenge, drug resistant bacteria are developing faster than new antibiotics can reach the market. The campaign targets increasing awareness of AMR among patients and public, finding solutions, and driving a political movement – with the ABPI working alongside patient groups and charities on a wide-scale digital push.

Elliot Dunster, Executive Director, Corporate Affairs & Devolved Nations, ABP



14.30 Drive Digital Communications & Social Media Strategies Forwards For Pharma & Healthcare Organisations With New Channels & Engaging & Informative Content To Increase Cut-Through With Key Stakeholders

  • Employ the best digital and social media channels for your comms mission to engage audiences creatively, create compelling narratives and achieve the results you want
  • Create strong digital communications strategies which keep pace with the latest public trends, tech and algorithm updates to ensure that your messages are relevant, impactful, compliant and in line with the brand
  • In a noisy, crowded digital landscape, how can you best manage multi-channel comms capacities to optimise resources and develop strong, online presences on key platforms
  • From education to support, what role can social media play in improving the health and wellbeing of the public and raise awareness and reputational standing for pharma?

Liselle Mulcairem, Global Head, Medical Omnichannel Engagement, Novartis



Hayley Wood, Head of Public & Media Relations Corporate Communications, Bayer



Luke Mircea-Willats Director, Media Relations & Communications, International, Moderna



Elliot Dunster, Executive Director, Corporate Affairs & Devolved Nations, ABPI


15.00 From “In It Together” To Economic Squeezes, How Can We Create Clear Communications Between Pharma, Healthcare Organisations & Government To Build Back Better Post-COVID & Secure Long-Term Engagement

  • Harness the “whatever it takes” pandemic spirit and the collaboration between government and healthcare organisations to see us through the current “the coffers are empty” stage… how can we improve relations to protect future investments?
  • Change on a massive scale: with upcoming changes in market access across Europe, how can we prepare ourselves and communicate clearly throughout this new process to increase understanding around value added
  • Partner with other industry stakeholders and carry your voice to government and media to highlight the boost in jobs and healthcare that can result from investment and protection of innovation in the sector
  • Beyond COVID… there are infinite other health conditions which need a spotlight, so how can we better communicate with the Government around health?

Matthijs Van Meerveld, Head of Global Public Affairs, Breast Cancer, Sanofi



Anne-Claire Poinas, Director Global Market Access & Public Affairs, Norgine


Anita Ralli, Associate Director of Government Affairs, Gilead Sciences


Paul Lehmann, Corporate Affairs Director, Spire Healthcare Group plc


Klark Mullen, Associate Director, Therapeutic Area Government Affairs, Astellas Europe plc


Alessandro Tempra, Head of Public Policy & Government Affairs Europe Canada Partner Markets, Biogen

15.30 Bonus Session; Reserved For Exclusive Conference Partner

16.00 Afternoon Refreshment Break With Informal Networking


16.30 Strategic Communications Approaches To Create Compelling, Convincing Cases Which Win Over Key Stakeholders

  • With the price squeeze from inflation and supply challenges, as well as hard negotiations with buyers and governmental measures such as clawback taxes, how can pharmaceuticals drive towards win-win outcomes?
  • With incoming legislation on equity and reach, what comms approaches actually resonate with key stakeholders to demystify market access, the cost of innovation and switch the narrative from “price” to “value added”
  • Build the business case for better: how can you convince stakeholders of the importance of investing in future health outcomes now instead of short term mindsets driven by economic pressures
  • How can pharma best harness genuine patient advocacy around ground-breaking innovations in genomics, rare diseases, oncology, dementia and more to cut through to decision-makers?

Speaker to be announced, please check the websites for updates.


16.50 Strategic Approaches For Strong, Impactful Internal Communications Which Win Over Internal Colleagues, Build Pride & Advocacy & Cultivate Resilient, Engaged Workforce Cultures

  • Build pride in what we do! Share success stories internally to increase employee connection to the company purpose and help everyone feel a sense of shared ownership and advocacy
  • As the digital workplace and available channels have exploded, how can we be mindful of information overload and digital fatigue in our communications?
  • On the pulse! Dial up surveys and feedback to be mindful of what colleagues really want from their company and own careers, and anticipate and tackle challenges in hybrid workspaces
  • Evidence the impact of comms on strategic goals to raise the internal profile of communications internally with leadership and ongoing secure investment and backing

Justyna Joanna Konczalska, Head of Communications & External Engagement, Germany, Sandoz

17.10 Afternoon Co-Chairs’ Closing Remarks & Official Close Of Conference

Global Insight Conferences is a rapidly-expanding and highly entrepreneurial conference company. We only employ individuals who are passionate about conferences, passionate about their personal growth and performance and passionate about being the best. Please send your CV with a covering letter to